health canada approval zepbound tirzepatide obesity canada 2024 2025 Pharmacotherapy for management in adults: CPG update webinar Zepbound (Mounjaro/Tirzepatide) for weight management

Combining injections with healthy lifestyle choices ensures the best results

Z90.3 is a status code, and CMS Medicare Code Edits list it as an unacceptable principal diagnosis

Case reports and clinical observations suggest that patients achieving significant weight loss on GLP-1 therapy experience parallel improvements in psoriasis activity scores, reduced need for topical corticosteroids, and faster healing of active plaques

Typical conversions from animal studies use body-surface-area scaling: Rat dose: 10 g/kg human equivalent ( 0.162) 1.6 g/kg For a 70 kg adult: ~112 g per day Self-experiment protocols often cite 100200 g once or twice daily via subcutaneous injection